1. A pharmaceutical composition for treating heart diseases comprising a nucleic acid which encodes mkRNK capable of eliciting proliferation kardiomiotsitov.2. A pharmaceutical composition according to claim 1, wherein mkRNK is a substance selected from the group consisting of mature mkRNK, mkRNK said precursor, and also its variants and analogov.3. A pharmaceutical composition according to claim 1 or 2, wherein mkRNK is a substance comprising a seed sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2.4. A pharmaceutical composition according to claim 3, wherein the substance containing the seed sequence set forth in SEQ ID NO: 1, is a material selected from the group consisting of miR-148a (SEQ ID NO: 3), miR-148b (SEQ ID NO : 5), miR-152 (SEQ ID NO: 7), their precursors and their variants and analogov.5. A pharmaceutical composition according to claim 3, wherein the substance comprising a seed sequence shown in SEQ ID NO: 2, is a substance selected from the group consisting of miR-373 (SEQ ID NO: 9) and its precursors, as well as its variants and analogov.6. A pharmaceutical composition according to claim 1 or 2, wherein the nucleic acid which encodes mkRNK capable of causing the proliferation of cardiomyocytes contained in the form of an expression vector for administration and expression in kardiomiotsitah.7. A pharmaceutical composition according to claim 6, wherein the vector is a viral vektor.8. A pharmaceutical composition according to claim 1 or 2, wherein mkRNK mkRNK is a derivative containing at least one modified internucleoside linkage, at least one modified sugar group, at least one modified base or any1. Фармацевтическая композиция для лечения заболеваний сердца, содержащая нуклеиновую кислоту, которая кодирует мкРНК, способную вызывать пролиферацию кардиомиоцитов.2. Фармацевтическая композиция по п.1, где мкРНК представляет собой вещество, выбранное из группы, состоящей из зрелой мкРНК, предшественника указанной мкРНК, а также ее вариантов и аналогов.3. Ф
